HeartBeam Inc. has enrolled the first patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The enrollment was conducted by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, marking a critical step toward generating clinical data needed to expand the technology's indication beyond arrhythmia assessment.
The company's technology represents a significant advancement in cardiac monitoring as it creates the first cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located, delivering actionable heart intelligence directly to physicians who can then identify cardiac health trends and acute conditions outside traditional medical facilities.
For business and technology leaders, this development signals a potential transformation in cardiac health management. The ability to detect heart attacks through portable technology could dramatically reduce time-to-diagnosis and enable earlier intervention, potentially saving lives while reducing healthcare system burdens. The technology's portability addresses a significant gap in current cardiac care, where traditional ECG monitoring requires clinical settings and specialized equipment.
The HeartBeam System with 12-lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025, according to the company's cleared indications for use available at https://www.heartbeam.com/indications. The company holds over 20 issued patents related to technology enablement, providing intellectual property protection for this innovative approach to cardiac monitoring.
Industry implications are substantial as this technology could redefine remote patient monitoring and telemedicine capabilities. For healthcare providers, the ability to obtain comprehensive cardiac data remotely could enable more proactive care management and reduce unnecessary emergency department visits. For patients, particularly those in rural areas or with mobility limitations, this technology promises greater access to sophisticated cardiac monitoring without requiring travel to medical facilities.
The ALIGN-ACS study represents a strategic expansion of HeartBeam's technology platform. Successful results could position the company at the forefront of portable cardiac diagnostics, creating new market opportunities in both consumer and clinical healthcare segments. The technology's potential to detect heart attacks early could have significant public health implications, particularly for populations with limited access to immediate medical care.
As the study progresses, the medical community will be watching closely for data demonstrating the system's effectiveness in heart attack detection. The successful expansion of indications could validate HeartBeam's approach to transforming cardiac care through portable, three-dimensional ECG technology that brings sophisticated diagnostics directly to patients wherever they may be.
